EFM
CCCC icon

E Fund Management’s C4 Therapeutics CCCC Stock Holding History

E Fund Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,280
Closed -$52.1K – 357
2024
Q2 		$52.1K Sell
11,280
-28,116
-71% -$168K ﹤0.01% 317
2024
Q1 		$322K Buy
+39,396
New +$305K 0.02% 270

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

E Fund Management's CCCC Position: Q3 2024 in Review

E Fund Management sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 11,280 shares — an estimated $52.1K sold.

E Fund Management first reported a position in CCCC in Q1 2024 and held it in 2 quarters. The position peaked at $322K in Q1 2024. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • E Fund Management reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • E Fund Management sold 11,280 C4 Therapeutics shares in Q3 2024, an estimated $52.1K.
  • E Fund Management first reported a position in C4 Therapeutics in Q1 2024 and held it in 2 quarters.
  • E Fund Management's C4 Therapeutics position peaked at $322K in Q1 2024.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on E Fund Management's 13F filing for Q3 2024, filed 13 Nov 2024.